Document:

Exhibit 10.3 

 

THIS AGREEMENT is made on 24 / 09 / 2021.

 

BETWEEN

 

		(1)	EXSCIENTIA AI LIMITED, a company registered in Scotland with registered number SC428761 and having its registered office at
Level 3, Dundee One River Court, 5 West Victoria Dock Road, Dundee, United Kingdom (the “Company”); and

 

		(2)	BEN TAYLOR, residing at 39 The Lion Brewery, Oxford, Oxfordshire, OX1 1JE (the “Executive”).

 

BACKGROUND

 

On and from the Effective Date, the Company wishes
to employ the Executive as Chief Strategy Officer and Chief Financial Officer on the terms and conditions of this Agreement and the Executive
wishes to accept such terms of employment.

 

IT IS AGREED as follows:

 

		1.	DEFINITIONS AND INTERPRETATION

 

		1.1.	Definitions

 

In this Agreement, unless
the context otherwise requires:

 

	“Basic Salary”	means the salary, as specified in Clause 6.1(a) or, as appropriate, the reviewed annual salary from time to time;
	“Board”	means the Board of directors of the Parent from time to time or any duly authorised committee thereof, or where the relevant powers have been reserved to the Parent’s members, its members from time to time;
	“Cause”	Means as defined in clause 17.1;
	“Change in Control”	means as defined in the Parent’s 2021 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan;

 

     

     

    

 

	“Confidential Information”	means all information which is identified or treated by the Company or any Group Company or any of the Group’s clients or customers as confidential or which by reason of its character or the circumstances or manner of its disclosure is evidently confidential including (without prejudice to the foregoing generality) any information about the personal affairs of any of the directors (or their families) of the Company or any Group Company, business plans, proposals relating to the acquisition or disposal of a company or business or proposed expansion or contraction of activities, maturing new business opportunities, research and development projects, designs, secret processes, trade secrets, product or services development and formulae, know-how, inventions, sales statistics and forecasts, marketing strategies and plans, costs, profit and loss and other financial information (save to the extent published in audited accounts), prices and discount structures and the names, addresses and contact and other details of: (a) employees and their terms of employment; (b) customers and potential customers, their requirements and their terms of business with the Company or Group; and (c) suppliers and potential suppliers and their terms of business (all whether or not recorded in writing or in electronic or other format);
	“Effective Date”	means the date of the underwriting agreement between the Parent and the underwriter(s) managing the initial public offering of the Parent’s ordinary shares (or securities representing such ordinary shares), pursuant to which such securities are priced for the initial public offering;
	“Employment”	means the employment of the Executive under this Agreement or, as the context requires, the duration of that employment;

 

    2 

     

    

 

	“Good Reason”	means any of the following actions taken by the Company without the Executive’s express written consent: (i) a material reduction by the Company of the Basic Salary (other than in a broad based reduction similarly affecting all other members of the Group’s executive management); (ii) the relocation of the Executive’s principal place of employment, without the Executive’s consent, in a manner that lengthens the Executive’s one-way commute distance by fifty (50) or more miles from the Executive’s then-current principal place of employment immediately prior to such relocation; (iii) a material reduction in the Executive’s duties, authority, or responsibilities for the Company relative to the Executive’s duties, authority, or responsibilities in effect immediately prior to such material reduction; or (iv) a material breach of this Agreement by the Company (or its successor) provided further, that, any such termination by the Executive shall only be deemed for Good Reason pursuant to this definition if: (1) the Executive gives the Chief Executive Officer written notice of intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that the Executive believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); (3) the Company has not, prior to the Chief Executive Officer receiving such notice from the Executive, already informed the Executive in writing that their employment with the Company is being terminated; and (4) the Executive voluntarily terminates their employment within thirty (30) days following the end of the Cure Period;
	“Group”	means together or separately the Parent, the Company, any holding company or undertaking of the Parent or the Company and any subsidiaries and subsidiary undertakings of the Parent of the Company or such holding company or holding companies or undertaking from time to time (and the words “subsidiary” and “holding company” shall have the meanings given to them in section 1159 in the Companies Act 2006);
	“Group Company”	means any company within the Group;
	“Health Care Scheme”	means any healthcare or disability scheme(s) or arrangement(s) as may be provided or introduced from time to time by the Company (at the Company’s discretion) for the benefit of similarly situated executives in the Company or Group;
	“Intellectual Property Rights”	means any and all existing and future intellectual or industrial property rights in and to any Works (whether registered or unregistered), including all existing and future patents, copyrights, design rights, database rights, trade marks, semiconductor topography rights, plant varieties rights, internet rights/domain names, know-how and any and all applications for any of the foregoing and any and all rights to apply for any of the foregoing in and to any Works;
	“Minority Holder”	means a person who either solely or jointly holds (directly or through nominees) any shares or loan capital in any company, whether or not it is listed or dealt in on a recognised stock exchange, provided that such holding does not, when aggregated with any shares or loan capital held by the Executive’s partner and/or his or his partner’s children under the age of 18, exceed 5% of the shares or loan capital of the class concerned for the time being issued;
	“Parent”	means Exscientia Limited, incorporated in England with company number 13483814;
	“Remuneration Committee”	means the remuneration committee appointed by the Board;
	“Schemes”	means the Health Care Scheme and such other benefit schemes in which other UK-based members of the Group’s executive management are entitled to participate (each a “Scheme”);

 

    3 

     

    

 

	“Settlement Agreement”	means a settlement agreement that includes, among other terms, a general release of claims in favour of the Company and each Group Company (subject to standard carve-outs preserving the Executive’s rights to accrued pension benefits), as well as mutual non-disparagement provisions, in a form presented by the Company and to be negotiated by the parties acting reasonably and in good faith;
	“Termination Date”	means the date of termination of the Employment;
	“Works”	means any documents, materials, models, designs, drawings, processes, inventions, formulae, computer coding, methodologies, know-how, Confidential Information or other work, performed made, created, devised, developed or discovered by the Executive during the course of the Employment either alone or with any other person in connection with or in any way affecting or relating to the business of the Company or any Group Company or capable of being used or adapted for use therein or in connection therewith;

 

		1.2.	Interpretation and Construction

 

Save to the extent that the context
or the express provisions of this Agreement require otherwise, in this Agreement:

 

		(a)	words importing the singular shall include the plural and vice versa;

 

		(b)	words importing any gender shall include all other genders;

 

		(c)	words importing the whole shall be treated as including reference to any part of the whole;

 

		(d)	any reference to a Clause, the Schedule or part of the Schedule is to the relevant Clause, Schedule or
part of the Schedule of or to this Agreement unless otherwise specified;

 

		(e)	reference to this Agreement or to any other document is a reference to this Agreement or to that other
document as modified, amended, varied, supplemented, assigned, novated or replaced from time to time;

 

		(f)	reference to a provision of law is a reference to that provision as extended, applied, amended, consolidated
or re-enacted or as the application thereof is modified from time to time and shall be construed as including reference to any order,
instrument, regulation or other subordinate legislation from time to time made under it;

 

		(g)	references to a “person” includes any individual, firm, company, corporation, body corporate,
government, state or agency of state, trust or foundation, or any association, partnership or unincorporated body (whether or not having
separate legal personality) or two or more of the foregoing;

 

    4 

     

    

 

		(h)	general words shall not be given a restrictive meaning because they are followed by words which are particular
examples of the acts, matters or things covered by the general words and “including”, “include” and “in
particular” shall be construed without limitation; and

 

		(i)	the meaning of any words coming after “other” or “otherwise” shall not be constrained
by the meaning of any words coming before “other” or “otherwise where a wider construction is possible.

 

		1.3.	Headings

 

The table of contents and the headings
in this Agreement are included for convenience only and shall be ignored in construing this Agreement.

 

		2.	THE EMPLOYMENT

 

		2.1.	Effectiveness and Appointment

 

This Agreement is effective as of, and
contingent upon, the occurrence of the Effective Date.

 

Subject to the provisions of this Agreement,
the Company employs the Executive and the Executive accepts employment as Chief Strategy Officer and Chief Financial Officer of the Company
on the terms of this Agreement.

 

		2.2.	Work Permits and warranty

 

The Executive warrants that he is legally
entitled to work in the United Kingdom and will throughout the Employment continue to hold a valid United Kingdom work permit if appropriate.
The Executive warrants that he will notify the Company in advance of any possible change to his immigration status, as soon as he becomes
aware of any circumstances that might give rise to such change. Should the Company discover that the Executive does not have permission
to live and work in the United Kingdom or if any such permission is revoked, notwithstanding any other term of this Agreement the Company
reserves the right to terminate the Employment immediately and without notice or pay in lieu of notice and without referring to the warning
stages of the Company’s disciplinary procedure. Notwithstanding any of the foregoing, the Company will not during the Employment
unilaterally take action to revoke the Executive’s permission to work in the United Kingdom, unless required by law to do so.

 

		3.	DURATION OF THE EMPLOYMENT

 

		3.1.	Continuous Employment

 

The Executive’s continuous period
of employment with the Company commenced on 17 November 2020. No previous employment shall count as part of the Executive’s continuous
period of employment.

 

		3.2.	Duration

 

Subject to the provisions of Clauses
3 and 17 (including clauses 17.4 and 17.5 thereof) the Employment shall continue unless and until terminated at any time by:

 

		(a)	the Company, which must give to the Executive not less than six months’ prior written notice of
termination of the Employment; or

 

		(b)	the Executive, who must give to the Company not less than six months’ prior written notice of termination
of the Employment.

 

    5 

     

    

 

		3.3.	Payment in lieu of notice

 

		(a)	The Company shall be entitled, at its sole discretion, to terminate the Employment immediately at any
time by giving the Executive notice in writing. In these circumstances, subject to the terms of Clause 3.3(b), the Company will subsequently
make a payment to the Executive in lieu of notice, calculated in accordance with the provisions of Clause 3.3(c) (the payment being referred
to as a “PILON”).

 

		(b)	The PILON will be paid in equal monthly instalments less all deductions that are required or permitted
by law to be made including in respect of income tax, national insurance contributions and any sums due to the Company or any Group Company.

 

		(c)	The PILON will consist of a sum equivalent to the Basic Salary which the Executive would have received
in respect of any notice period outstanding on the Termination Date but will exclude (except to the extent expressly provided in this
Agreement) any bonus, commission and share of profit and any other benefits which he would have received or would have accrued to him
during that period.

 

		4.	HOURS AND PLACE OF WORK

 

		4.1.	Hours of work

 

The Executive agrees that he shall work
normal business hours together with such additional hours as are necessary for the proper performance of his duties.

 

		4.2.	Working Time Regulations

 

The Executive has autonomous decision-making
powers. The duration of his working time is not measured or predetermined. The Executive agrees that his employment falls within Regulation
20 of the Working Time Regulations 1998.

 

		4.3.	Place of work

 

		(a)	The Executive’s normal place of work will be at the Company’s offices at Oxford, but the Company
may require the Executive to work at any place within the United Kingdom on either a temporary or an indefinite basis. The Executive will
be given reasonable notice of any change in his permanent place of work.

 

		(b)	The Executive may be requested to be absent from the United Kingdom for a period exceeding 1 month at
any one time, but there are not currently any particulars to be entered in this regard1.

 

 

1 Note to draft:
For Garry and Dave this provision shall read “There is no current requirement for the Executive to work outside the United Kingdom
for any consecutive period of one month or more.”

 

    6 

     

    

 

		5.	SCOPE OF THE EMPLOYMENT

 

		5.1.	Duties of the Executive

 

During the Employment the Executive
shall:

 

		(a)	undertake and carry out to the best of his ability such duties and exercise such powers in relation to
the Company or Group’s business as may from time to time be assigned to or vested in him by the Board including where those duties
require the Executive to work for any Group Company;

 

		(b)	in the discharge of those duties and the exercise of those powers observe and comply with all lawful resolutions,
regulations and directions from time to time made by, or under the authority of, the Board and promptly upon request, give a full account
to the Board or a person duly authorised by the Board of all matters with which he is involved. He will provide the information in writing
if requested;

 

		(c)	comply with the Articles of Association (as amended from time to time) of the Parent, the Company and
any Group Company;

 

		(d)	do, or refrain from doing, such things as are necessary or expedient to ensure compliance by himself,
the Parent, the Company and any Group Company with applicable law and regulations and all regulatory authorities relevant to the Parent,
the Company and any Group Company, and any codes of practice issued by the Parent, the Company and any Group Company (as amended from
time to time);

 

		(e)	act in accordance with all statutory, fiduciary and common law duties that he owes to the Parent, the
Company and any Group Company;

 

		(f)	refrain from doing anything which would cause him to be disqualified from acting as a director;

 

		(g)	unless prevented by ill-health, holidays or other unavoidable cause, devote the whole of his working time,
attention and skill to the business of the Parent, the Company and Group Companies and the discharge of his duties hereunder;

 

		(h)	faithfully and diligently perform his duties and at all times use his best endeavours to promote and protect
the interests of the Parent, the Company and the Group;

 

		(i)	promptly disclose to the Board full details of any wrongdoing by the Executive or any other employee of
any Group Company where that wrongdoing is material to that employee’s employment by the relevant company or to the interests or
reputation of any Group Company.

 

		5.2.	Right to suspend duties and powers

 

		(a)	During any notice period or for the purpose of investigating any matter in which the Executive is implicated
or involved, the Company reserves the right in its absolute discretion to suspend all or any of the Executive’s duties and powers
on terms it considers expedient or to require him to perform only such duties, specific projects or tasks as are assigned to him expressly
by the Company (including the duties of another position) in any case for such period or periods and at such reasonable place or places
(including, without limitation, the Executive’s home) as the Company in its absolute discretion deems necessary (the “Garden
Leave”). During any period of Garden Leave the terms and conditions set out in this Agreement shall continue to apply to the
Executive.

 

    7 

     

    

 

		(b)	The Company may, at its sole discretion, require that during the Garden Leave the Executive shall not:

 

		(i)	enter or attend the premises of the Parent, the Company or any Group Company;

 

		(ii)	contact or have any communication with any client or prospective client or supplier of the Parent, the
Company or any Group Company in relation to the business of the Parent, the Company or any Group Company;

 

		(iii)	contact or have any communication with any employee, officer, director, agent or consultant of the Parent,
the Company or any Group Company in relation to the business of the Parent, the Company or any Group Company, save that this restriction
shall (A) not prevent the Executive from contacting and communicating with his family members, and (B) be without prejudice to the Executive’s
rights as shareholder of the Parent or duties as a director of any Group Company;

 

		(iv)	remain or become involved in any aspect of the business of the Parent, the Company or any Group Company
except as required by such companies; or

 

		(v)	work either on his own account or on behalf of any other person.

 

		(c)	During Garden Leave, the Executive will continue to receive his Basic Salary and benefits but will not
(except to the extent expressly provided in this Agreement) accrue any bonus, commission or share of profit.

 

		(d)	If the Executive is suspended, other than during any notice period, for the purpose of investigating any
matter in which the Executive is implicated or involved and the Executive is subsequently exonerated, the Executive will be paid any amounts
not paid to the Executive in respect of the period of suspension where such amounts would have otherwise been paid were it not for the
operation of Clause5.2(c).

 

		(e)	For the avoidance of doubt, the Company may exercise its powers under this Clause 5.2 at any time during
the Employment including after notice of termination has been given by either party.

 

		6.	REMUNERATION

 

		6.1.	Basic Salary

 

		(a)	During the Employment the Company shall pay the Executive a Basic Salary of not less than £275,000
per annum. The Basic Salary will increase to £310,000 per annum as of the 1st of January 2022. The Basic Salary shall
accrue from day to day and be payable by credit transfer in equal monthly instalments in arrears on or around the 25th day of each calendar
month or otherwise as arranged from time to time.

 

		(b)	The Basic Salary shall be inclusive of all director’s fees (if any) to which the Executive may become
entitled including all remuneration and director’s fees in respect of services rendered by the Executive to any Group Company (including,
without limitation, the Parent).

 

    8 

     

    

 

		6.2.	Salary review

 

The Basic Salary shall be reviewed annually.
The Company is not obliged to increase the Basic Salary at any review.

 

		6.3.	Annual bonus

 

		(a)	Subject to clause 6.3(b), the Executive shall be eligible to receive an annual performance bonus (the
“Annual Bonus”) with an annual target of 35% (the “Target Percentage”) of the Executive’s
then-current Base Salary (the “Target Bonus”). The Annual Bonus will be based upon the assessment of the Board (or
a committee thereof) of the Executive’s performance and Group’s attainment of targeted goals (as established by the Board
or a committee thereof in its sole discretion) over the applicable calendar year. The Annual Bonus, if any, will be subject to applicable
payroll deductions and withholdings. No amount of any Annual Bonus is guaranteed at any time, and, except as otherwise expressly stated
in clause 17 of this Agreement, the Executive must be an employee in good standing (without having given or received notice) through the
date of payment of the Annual Bonus in order to be eligible to receive an Annual Bonus and no partial or prorated bonuses will be provided.
Unless otherwise stated in clause 17 of this Agreement, any Annual Bonus, if awarded, will be paid by the Company after receipt by the
Parent of the audited financial statements of the Parent for the financial year in question, but no later than 31 May of the year following
the year to which such bonus relates, and will be paid in cash or in securities, as determined by the Board (or committee thereof). Any
Annual Bonus will be subject to recoupment in accordance with any clawback policy that the Parent or the Company is required to adopt
pursuant to the listing standards of any national securities exchange or association on which the Parent’s or any Group Company’s
securities are listed or as is otherwise required by applicable law and any clawback policy that the Parent or the Company otherwise adopts,
to the extent applicable and permissible under applicable law. No recovery of compensation under such a clawback policy will be an event
giving rise to Good Reason. Except as otherwise stated in clause 17 of this Agreement, in the event the Executive leaves the employment
of the Company for any reason prior to the date the Annual Bonus is paid, the Executive is are not eligible to earn such Annual Bonus,
prorated or otherwise.

 

		(b)	In respect of the 2021 calendar year the Executive’s Annual Bonus target shall be calculated as
follows: (a) an amount equal to the prorated portion of the Executive’s Annual Bonus target for the 2021 calendar year as in effect
immediately prior to the Effective Date (calculated using the number of days in the 2021 calendar year that have passed between 1 January
2021 and the date immediately preceding the Effective Date); plus (b) an amount equal to the prorated portion of the Target
Bonus as in effect on the Effective Date (calculated using the number of days in the 2021 calendar year that have passed between (and
including) the Effective Date and 31 December 2021).

 

		6.4.	Directors’ Remuneration Policy. 

 

Executive understands
and agrees that, if and for so long as the Executive is a director of the Parent, the Executive’s remuneration shall be subject
to the terms of the Directors’ Remuneration Policy as may be adopted by the Parent in accordance with applicable law from time to
time.

 

    9 

     

    

 

		7.	EXPENSES

 

		7.1.	Out-of-pocket expenses

 

The Company shall reimburse to the Executive
(against receipts or other appropriate evidence as the Board may require) the amount of all out-of-pocket expenses reasonably and properly
incurred by him in the proper discharge of his duties hereunder to the extent that such expenses are incurred in accordance with the Group’s
applicable business expenses policy from time to time.

 

		8.	DEDUCTIONS

 

The Executive agrees that the Company
may deduct from any sums due to him under this Agreement any sums due by him to any Group Company including, without limitation, any debits
to his Company credit or charge card not authorised by the Company, the Executive’s pension contributions (if any), any overpayments,
loans or advances made to him by any Group Company, the cost of repairing any damage or loss to the Company’s property intentionally
caused by him.

 

		9.	PENSION SCHEME

 

During the period of the Executive’s
service with the Company, the Company will comply at all times with the employer duties under Part 1 of the Pensions Act 2008. Further
details of the Executive’s pension entitlement are set out in the Company’s Staff Handbook.

 

		10.	OTHER INSURANCE & BENEFITS

 

		10.1.	Benefit Schemes

 

Without prejudice to the terms of Clauses
3 and 17, the Executive shall be entitled during the Employment, to participate at the Company’s expense in any Schemes subject
to the following terms and conditions:

 

		(a)	the Executive’s participation is subject to the Company’s rules regarding eligibility in force
from time to time and the rules, terms and conditions of the Scheme and/or insurance policy in force from time to time;

 

		(b)	the Company reserves the right to terminate the Executive’s or the Company’s participation
in any Scheme, substitute a new scheme(s) for an existing scheme(s) and/or alter the level or type of benefits available under any scheme(s)
(provided that the Executive’s eligibility to participate in the Schemes and the level and type of benefits will be broadly equivalent
as that available to other UK-based members of the Group’s executive management);

 

		(c)	if a Scheme provider (e.g. an insurance company or pensions provider) refuses for any reason (whether
under its own interpretation of the rules, terms and conditions of the relevant insurance policy or otherwise) to accept a claim and/or
provide the relevant benefit(s) to the Executive under the applicable Scheme, the Company shall not be liable to provide (or compensate
the Executive for the loss of) such benefit(s) nor shall it be obliged to take action against the provider to enforce any rights under
the Scheme;

 

		(d)	the fact that the termination of the Employment may result in the Executive ceasing to be eligible to
receive or continue to receive benefits under any Scheme does not remove the Company’s right to terminate the Employment.

 

    10 

     

    

 

		10.2.	Medical examinations

 

At any reasonable time during the Employment
the Company may require the Executive to undergo a medical examination by a medical practitioner appointed by the Company and at the Company’s
expense and the Executive will consent to such examination and to the results being made available to the Company.

 

		10.3.	Other leave 

 

The Executive
may be eligible for other forms of paid leave, subject to any statutory eligibility requirements or conditions and the Company's rules
applicable to each type of leave in force from time to time. Further details of such leave are available in the Company’s Staff
Handbook. The Company may replace, amend or withdraw the Company's policy on any types of leave at any time (provided that the Executive’s
eligibility to for such leave will be broadly equivalent as that available to other UK-based members of the Group’s executive management).

 

		11.	HOLIDAYS

 

		11.1.	The holiday year

 

The Company’s holiday year runs
from 1st January to 31st December. Holidays can only be taken with the prior agreement of the CEO (such agreement not be withheld unreasonably).

 

		11.2.	Annual entitlement

 

		(a)	The Executive shall be entitled to 28 days' paid holiday in each holiday year excluding the usual public
holidays in England.

 

		(b)	Entitlement to contractual holidays is accrued pro rata throughout the holiday year. The Executive will
be entitled to take public and customary holidays on the days that they are recognised by the Company during the holiday year.

 

		(c)	The Executive may carry any unused holiday entitlement forward to the next holiday year in accordance
with the Company’s policy on holidays as may apply from time to time.

 

		11.3.	Holiday entitlement on termination

 

Upon notice of termination of the Employment
being served by either party, the Company may require the Executive to take any unused holidays accrued in the holiday year in which the
termination takes place during any notice period. Alternatively, the Company may, at its discretion, on termination of the Employment,
make a payment in lieu of accrued contractual holiday entitlement. The Executive will be required to make a payment to the Company in
respect of any holidays taken in excess of his holiday entitlement accrued at the Termination Date. Any sums so due may be deducted from
any money owing to the Executive by the Company.

 

		12.	TRAINING

 

As at the date of this Agreement, the
Executive is not required to undertake any particular training. If any particular training is required or offered, details will be provided.

 

    11 

     

    

 

 

	13.	ABSENCE

 

	13.1.	Absence due to sickness or injury

 

If the Executive is unable to perform
his duties due to sickness or injury he shall:

 

		(a)	as soon as practicable inform the CEO and the Head of Human Resources of his sickness or injury; and

 

		(b)	In respect of inability to perform duties due to sickness, injury or accident that continues for more
than 7 consecutive days (including weekends) the Executive must provide the Company with a note of fitness to work stating the reason
for the absence. Thereafter notes of fitness to work must be provided to the Company to cover the remainder of the period of continuing
sickness absence. Failure to follow these requirements may result in disciplinary action and loss of Statutory Sick Pay and/or sick pay
pursuant to Clause 13.2.

 

	13.2.	Payment of salary during absence

 

		(a)	Subject to the Executive complying with the terms of Clause 13.1, the Company will continue to pay Basic
Salary and other benefits during any period of the Executive’s inability to perform his duties due to sickness or injury for up
to a maximum period of 4 weeks (according to the Company’s Staff Handbook) in any period of 12 consecutive months (the 12 month
period referred to as the “Entitlement Period”) and thereafter a sum equivalent to Statutory Sick Pay only during any
further period of the Executive’s inability to perform his duties due to sickness or injury in the same Entitlement Period for up
to a maximum period of 28 weeks unless the Employment is terminated in terms of Clauses 3 or17. The first Entitlement Period will begin
on the first day of absence and any subsequent Entitlement Period will start on the first day of any absence occurring outside an enduring
Entitlement Period.

 

		(b)	Payment of the Basic Salary in terms of Clause 13.2(a) shall be made less:

 

		(i)	an amount equivalent to any Statutory Sick Pay payable to the Executive;

 

		(ii)	any sums which may be received by the Executive under any insurance policy effected by the Company; and

 

		(iii)	any other benefits or sums which the Executive receives (e.g. under a PHI or other insurance scheme) in
connection with the Employment or under any relevant legislation.

 

		(c)	Once payment of Basic Salary under Clause 13.2(a) ceases, then the Executive shall have no right to any
sickness or injury payment, benefit or emolument from the Company.

 

	13.3.	Absence caused by third party negligence

 

If the Executive’s inability to
perform his duties is caused by the negligence of a third party in respect of which damages are recoverable, then all sums paid by the
Company during the period of absence shall constitute loans to the Executive who shall:

 

		(a)	immediately notify the Company of all the relevant circumstances and of any claim, compromise, settlement
or judgment made or awarded; and

 

		(b)	if the Company so requires, refund to it an amount determined by the Company, not exceeding the lesser
of:

 

    12

     

    

 

		(i)	the amount of damages recovered by him in respect of past loss of earnings during the period of absence
under any compromise, settlement or judgment; and

 

		(ii)	the sums advanced to him by the Company in respect of the period of incapacity.

 

	14.	OTHER INTERESTS

 

	14.1.	Disclosure of other interests

 

The Executive shall disclose to the
Board any interest of his own (or that of his partner or of any child of his or of his partner under eighteen years of age, except where
such disclosure would be in or cause a breach of an obligation of confidentiality owed by such person to a third party):

 

		(a)	in any trade, business or occupation whatsoever which is in any way similar to any of those in which the
Parent, the Company or any Group Company is involved; and

 

		(b)	in any trade, business or occupation carried on by any supplier or customer of the Parent, the Company
or any Group Company whether or not such trade, business or occupation is conducted for profit or gain.

 

	14.2.	Restrictions on other activities and interests of the Executive

 

		(a)	During
the Employment, the Executive shall not at any time, without the prior written consent of the Board, either alone or jointly with any
other person, carry on or be directly or indirectly employed, engaged, concerned or interested in any business, prospective business
or undertaking other than a Group Company. Nothing contained in this Clause shall preclude the Executive from being a Minority Holder
unless the holding is in a company that is a direct business competitor of the Company or any Group Company, in which case the Executive
shall obtain the prior consent of the Board to the acquisition or variation of such holding.

 

		(b)	If the Executive, with the consent of the Board, accepts any other appointment he must keep the Board
accurately informed of the amount of time he spends working under that appointment.

 

	14.3.	Transactions with the Company

 

Subject to any regulations issued by
the Group, the Executive shall not be entitled to receive or obtain directly or indirectly any discount, rebate, commission or any other
form of gift or gratuity (any of these referred to as a “Gratuity”) as a result of the Employment or any sale or purchase
of goods or services effected or other business transacted (whether or not by him) by or on behalf of the Company or any Group Company
and if he (or any person in which he is interested) obtains any Gratuity he shall account to the Company for the amount received by him
(or a due proportion of the amount received by the person having regard to the extent of his interest therein).

 

    13

     

    

 

	15.	CONFIDENTIALITY AND COMPANY DOCUMENTS

 

	15.1.	Restrictions on disclosure and use of Confidential Information

 

The Executive must not either during
the Employment (except in the proper performance of his duties) or at any time (without limit) after the Termination Date:

 

		(a)	divulge or communicate to any person;

 

		(b)	use for his own purposes or for any purposes other than those of the Parent, the Company or any Group
Company; or

 

		(c)	through any failure to exercise due care and diligence, cause any unauthorised disclosure of;

 

any Confidential Information. The Executive
must at all times use his best endeavours to prevent publication or disclosure of any Confidential Information. These restrictions shall
cease to apply to any information which shall become available to the public generally otherwise than through the default of the Executive.
These restrictions shall not apply to any use or disclosure authorised by the Board or required by law, or any protected disclosure within
the meaning of section 43A of the Employment Rights Act 1996.

 

	15.2.	Protection of Company documents and materials

 

All notes, records, lists of customers,
suppliers and employees, correspondence, computer and other discs or tapes, data listings, codes, keys and passwords, designs, drawings
and other documents or material whatsoever (whether made or created by the Executive or otherwise and in whatever medium or format) relating
to the business of the Parent, the Company or any Group Company or any of its or their clients (and any copies of the same):

 

		(a)	shall be and remain the property of the Parent, the Company or the relevant Group Company or client; and

 

		(b)	shall be handed over by the Executive to the Parent, the Company or the relevant Group Company or client
on demand by the Company and in any event on the termination of the Employment.

 

	16.	INVENTIONS AND OTHER WORKS

 

	16.1.	Executive to further interests of the Company

 

The Company and the Executive agree
that the Executive may make or create Works in the course of the Employment and agree that in this respect the Executive is obliged to
further the interests of the Company and any Group Company.

 

	16.2.	Disclosure and ownership of Works

 

The Executive must immediately disclose
to the Company all Works and all Intellectual Property Rights. Both the Works and all Intellectual Property Rights will (subject to sections
39 to 43 Patents Act 1977) belong to and be the absolute property of the Company or any other person the Company may nominate.

 

    14

     

    

 

	16.3.	Protection, registration and vesting of Works

 

The Executive shall immediately on request
by the Company (whether during or after the Employment) and at the expense of the Company:

 

		(a)	apply or join with the Company or any Group Company in applying for any Intellectual Property Rights or
other protection or registration (“Protection”) in the United Kingdom and in any other part of the world for, or in
relation to, any Works;

 

		(b)	execute all instruments and do all things necessary for vesting all Intellectual Property Rights or Protection
when obtained and all right, title and interest to and in the same absolutely and as sole beneficial owner in the Company or such Group
Company or other person as the Company may nominate; and

 

		(c)	sign and execute any documents and do any acts reasonably required by the Company in connection with any
proceedings in respect of any applications and any publication or application for revocation of any Intellectual Property Rights or Protection.

 

	16.4.	Waiver of rights by the Executive

 

The Executive hereby irrevocably and
unconditionally waives all rights under Chapter IV Copyright, Designs and Patents Act 1988 and any other moral rights which he may have
in the Works, in whatever part of the world such rights may be enforceable including:

 

		(a)	the right conferred by section 77 of that Act to be identified as the author of any such Works; and

 

		(b)	the right conferred by section 80 of that Act not to have any such Works subjected to derogatory treatment.

 

	16.5.	Power of Attorney

 

The Executive hereby irrevocably appoints
the Company to be his attorney and in his name and on his behalf to execute any such act and to sign all deeds and documents and generally
to use his name for the purpose of giving to the Company the full benefit of this Clause. The Executive agrees that, with respect to any
third parties, a certificate signed by any duly authorised officer of the Company that any act or deed or document falls within the authority
hereby conferred shall be conclusive evidence that this is the case.

 

	16.6.	Statutory rights

 

Nothing in this Clause 16 shall be construed
as restricting the rights of the Executive or the Company under sections 39 to 43 Patents Act 1977.

 

	17.	TERMINATION

 

	17.1.	Termination events

 

Notwithstanding the provisions of Clauses
3 and 10, the Company shall be entitled, but not bound, to terminate the Employment with immediate effect (without a notice period or
payment in lieu of any notice period) by giving to the Executive notice in writing at any time after the occurrence of any one or more
of the following events (each being termination for “Cause”):

 

    15

     

    

 

		(a)	if the Executive is guilty of any gross misconduct or behaviour which tends to bring himself or the Company
or any Group Company into disrepute; or

 

		(b)	if the Executive commits any material or persistent breach of this Agreement (in the case of a non-material
persistent breach, having been given notice in writing of the breach and a reasonable opportunity to rectify the breach) or unreasonably
fails to comply with any reasonable order or direction of the Board; or

 

		(c)	if he becomes insolvent or bankrupt or compounds with or grants a trust deed for the benefit of his creditors;
or

 

		(d)	if his behaviour (whether or not in breach of this Agreement) can reasonably be regarded as materially
prejudicial to the interests of the Company or any Group Company, including if he is found guilty of any criminal offence punishable by
imprisonment (whether or not such sentence is actually imposed); or

 

		(e)	if he has an order made against him disqualifying him from acting as a company director; or

 

		(f)	if the Executive is found guilty of any offence of bribery under the Bribery Act 2010, or other bribery
legislation in any other jurisdiction, breach of Clause 15 of this Agreement or the Company’s Anti-Bribery and Corruption Policy;
or

 

		(g)	if the Executive commits any material breach or persistent but non-material breach of the Articles of
Association of the Company or any Group Company (in the case of a persistent but non-material breach, having been given notice in writing
of the breach and a reasonable opportunity to rectify the breach).

 

	17.2.	Termination on resignation as director

 

If the Executive resigns as a director
of the Company or any Group Company (otherwise than at the request of the Board or, in respect of a directorship of an entity other than
the Parent, with the prior agreement of the applicable Group Company), he shall be deemed to have voluntarily resigned from the Employment
with effect from the date of his resignation, unless the Company agrees with the Executive that the Employment should continue, in which
case the Employment may be subject to any terms and conditions stipulated by the Company in its absolute discretion.

 

	17.3.	No damages or payment in lieu of notice

 

In the event of the Employment being
terminated pursuant to Clause 17.1 the Executive shall not be entitled to receive any payment in lieu of notice nor make any claim against
the Company or any Group Company for damages for loss of office or termination of the Employment. Regardless of this, the termination
shall be without prejudice to the continuing obligations of the Executive under this Agreement.

 

    16

     

    

 

	17.4.	Termination by the Company without Cause or resignation by
the Executive for Good Reason (in connection with a Change in Control)

 

In the event that the Company terminates
the Executive’s Employment without Cause or the Executive resigns for Good Reason, in either case, within (3) three months prior
to, upon or within (12) twelve months following the effective date of a Change in Control (such period, the “Change in Control
Measurement Period”) then the Executive shall be entitled to his salary and benefits pursuant to the terms of this Agreement
through the Termination Date and, subject to the Executive (i) executing a Settlement Agreement; (ii) returning all Company property;
(iii) complying with the Executive’s termination and post-termination obligations under this Agreement; (iv) complying with the
terms of the Settlement Agreement, including without limitation any non-disparagement and confidentiality provisions contained therein;
and (v) resigning from any other positions held with the Company or any Group Company, including any position on the Board, effective
no later than the Termination Date (or such other date as requested by the Board), the Executive shall be eligible to receive the following
severance benefits (collectively the “CIC Severance Benefits”):

 

		(a)	The Company will pay the Executive severance pay in the form of continuation of the Executive’s
then-current Basic Salary (ignoring any decrease that forms the basis for the Executive’s resignation for Good Reason, if applicable)
for twelve (12) months following the Termination Date (such period of time, the “CIC Severance Period”, and such aggregate
Basic Salary amount payable, the “CIC Severance”). The CIC Severance will be paid in substantially equal instalments
on the Company’s regular payroll schedule over the CIC Severance Period, subject to such deductions as the Company is required by
law to make, shall be reduced by any Basic Salary received by the Executive during any period of Garden Leave and shall be inclusive of
any PILON; provided, however that no portion of the CIC Severance (except for any PILON instalment which is due) will be paid prior to
the date that the general release of claims in the Settlement Agreement becomes effective (the “Release Date”), and
any such payments that are otherwise scheduled to be made prior to the Release Date shall instead accrue and be made on the first regular
payroll date following the Release Date;

 

		(b)	The Company will pay to the Executive in monthly instalments, subject to such deductions as the Company
is required by law to make, a fully taxable cash payment equal to: (i) the coverage premium for the Executive (and the Executive’s
covered dependents, as applicable) health insurance coverage in effect on the Termination Date until the earliest of: (1) the close of
the CIC Severance Period or; (2) the date when the Executive becomes eligible for substantially equivalent health insurance coverage in
connection with new employment or self-employment; and (ii) the Company’s employer pension contributions that would have been received
by the Executive during the CIC Severance Period had Employment continued, at the rate payable by the Company immediately prior to the
Termination Date;

 

		(c)	The Company will make a lump sum cash payment to the Executive in an amount equal to one (1) times the
Target Bonus for the year in which the Termination Date occurs, subject to such deductions as the Company is required by law to make,
which will be paid in a lump sum on or before the 60th day following the Termination Date;

 

		(d)	The Company will make a lump sum cash payment to the Executive in an amount equal to any earned but unpaid
Annual Bonus for the year immediately preceding the year in which the Executive’s employment terminates, such payment to be made
no later than the normal payment date for such Annual Bonus; and

 

		(e)	Effective as of the Termination Date, the vesting and exercisability of all outstanding equity awards
covering the Parent’s ordinary shares that are held by the Executive immediately prior to the Termination Date shall be accelerated
in full.

 

    17

     

    

 

The CIC Severance Benefits provided
to the Executive pursuant to this clause 17.4 are in lieu of, and not in addition to, any benefits to which the Executive may otherwise
be entitled under any Company severance plan, policy, or program.

 

Any damages caused by the termination
of the Executive’s employment without Cause during the Change in Control Measurement Period would be difficult to ascertain; therefore,
the CIC Severance Benefits for which the Executive is eligible pursuant to this clause 17.4 in exchange for the Settlement Agreement are
agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty.

 

	17.5.	Termination by the Company without Cause or resignation by
the Executive for Good Reason (not in connection with a Change in Control)

 

In the event that the Company terminates
the Executive’s Employment without Cause or the Executive resigns for Good Reason, in either case, outside a Change in Control Measurement
Period then the Executive shall be entitled to his salary and benefits pursuant to the terms of this Agreement through the Termination
Date and, subject to the Executive (i) executing a Settlement Agreement; (ii) returning all Company property; (iii) complying with the
Executive’s termination and post-termination obligations under this Agreement; (iv) complying with the terms of the Settlement Agreement,
including without limitation any non-disparagement and confidentiality provisions contained therein; and (v) resigning from any other
positions held with the Company or any Group Company, including any position on the Board, effective no later than the Termination Date
(or such other date as requested by the Board), the Executive shall be eligible to receive the following severance benefits (collectively
the “Non-CIC Severance Benefits”):

 

		(a)	The Company will pay the Executive severance pay in the form of continuation of the Executive’s
then-current Basic Salary (ignoring any decrease that forms the basis for the Executive’s resignation for Good Reason, if applicable)
for twelve (12) months following the Termination Date (such period of time, the “Non-CIC Severance Period”, and such
aggregate Basic Salary amount payable, the “Non-CIC Severance”). The Non-CIC Severance will be paid in substantially
equal instalments on the Company’s regular payroll schedule over the Non-CIC Severance Period, subject to such deductions as the
Company is required by law to make, shall be reduced by any Basic Salary received by the Executive during any period of Garden Leave and
shall be inclusive of any PILON; provided, however that no portion of the Non-CIC Severance (except for any PILON instalment which is
due) will be paid prior to the date that the general release of claims in the Settlement Agreement becomes effective (the “Release
Date”), and any such payments that are otherwise scheduled to be made prior to the Release Date shall instead accrue and be
made on the first regular payroll date following the Release Date;

 

		(b)	The Company will pay to the Executive in monthly instalments, subject to such deductions as the Company
is required by law to make, a fully taxable cash payment equal to the coverage premium for the Executive (and the Executive’s covered
dependents, as applicable) health insurance coverage in effect on the Termination Date and/or provide the Executive with continued access
to the Company’s health insurance scheme until the earliest of: (1) the twelve (12) month anniversary of the date on which notice
to terminate the Employment is given in accordance with the terms of this Agreement or; (2) the date when the Executive becomes eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment;

 

    18

     

    

 

		(c)	The Company will pay the Executive an amount equal to the prorated portion of the Annual Bonus for the
calendar year in which the Termination Date occurs (calculated using the Target Bonus for the number of days in that calendar year that
have passed prior to the Termination Date or, if earlier, the date of commencement of any period of Garden Leave) (the “Pro-Rated
Bonus”). The Pro-Rated Bonus will be subject to standard deductions and withholdings and will be paid in a lump sum on or before
the 60th day following the Termination Date;

 

		(d)	The Company will make a lump sum cash payment to the Executive in an amount equal to any earned but unpaid
Annual Bonus for the year immediately preceding the year in which the Executive’s employment terminates, such payment to be made
no later than the normal payment date for such Annual Bonus; and

 

		(e)	Effective as of the Termination Date, the vesting and exercisability of all outstanding equity awards
covering the Parent’s ordinary shares that are held by the Executive immediately prior to the Termination Date shall be accelerated
such that Executive shall be treated, for vesting purposes, as if he had vested pro rata until the Termination Date or, if later, the
date on which his employment would have terminated had he not been paid a PILON (save that such equity awards shall not vest as to more
than 100 per cent.).

 

The Non-CIC Severance Benefits provided
to the Executive pursuant to this clause 17.5 are in lieu of, and not in addition to, any benefits to which the Executive may otherwise
be entitled under any Company severance plan, policy, or program.

 

Any damages caused by the termination
of the Executive’s employment without Cause outside the Change in Control Measurement Period would be difficult to ascertain; therefore,
the Non-CIC Severance Benefits for which the Executive is eligible pursuant to this clause 17.5 in exchange for the Settlement Agreement
are agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty.

 

	17.6.	Death or Disability

 

		(a)	In the event of the Executive’s death while employed pursuant to this Agreement, all obligations
of the parties hereunder and the Executive’s employment shall terminate immediately, but neither the Executive nor their legal representatives
will receive the CIC Severance Benefits or the Non-CIC Benefits. Notwithstanding the foregoing, nothing in this clause or in this Agreement
shall preclude the Executive from remaining eligible to receive any payments or benefits pursuant to any life assurance or permanent health
insurance policy under which the Executive participates, subject to and in accordance with the terms of this Agreement, such policy and
applicable law.

 

		(b)	Subject to applicable law, the Company shall at all times have the right, upon written notice to the Executive
in accordance with clause 3.2(a), to terminate this Agreement based on the Executive’s Disability (as defined below). Termination
by the Company of the Executive’s employment based on “Disability” shall mean termination because the Executive is unable
due to a physical or mental condition to perform the essential functions of their position (after taking into account any applicable reasonable
adjustments) for twelve (12) months in the aggregate during any eighteen (18) month period or based on the written certification by two
qualified licensed physicians of the likely continuation of such condition for such period. In the event the Executive’s employment
is terminated based on Disability, the Executive will not receive the CIC Severance Benefits or the Non-CIC
Benefits. Notwithstanding the foregoing, nothing in this clause or in this Agreement shall preclude the Executive from remaining eligible
to receive any payments or benefits pursuant to any life assurance or permanent health insurance policy under which the Executive participates,
subject to and in accordance with the terms of this Agreement, such policy and applicable law. The Company will not terminate this Agreement
if to do so would deprive the Executive of payments he is receiving under the Company’s applicable permanent health insurance scheme.

 

    19

     

    

 

	18.	EVENTS UPON TERMINATION

 

	18.1.	Obligations upon termination

 

Immediately upon the termination of
the Employment howsoever arising or immediately at the request of the Board at any time after either the Company or the Executive has
served notice of termination of the Employment, the Executive shall:

 

		(a)	deliver to the Company all Works, materials within the scope of Clause 15.2 and all other materials and
property including credit or charge cards, mobile telephone, computer equipment, disks and software, passwords, encryption keys or the
like, keys, security pass, letters, stationery, documents, files, films, records, reports, plans and papers (in whatever format including
electronic) and all copies thereof used in or relating to the business of the Company or the Group which are in the possession of or under
the control of the Executive;

 

		(b)	resign (without claim for compensation) as a director and from all other offices held by him in the Company
or any Group Company or otherwise by virtue of the Employment. For the avoidance of doubt, such resignations shall be without prejudice
to any claims the Executive may have against the Company or any Group Company arising out of the termination of the Employment; and

 

		(c)	transfer without payment, to the Company, or as the Company may direct, any shares or other securities
held by the Executive as nominee or trustee for the Company or any Group Company;

 

and should the Executive fail to do
so the Company is hereby irrevocably authorised to appoint some person to sign any documents and/or do all things in his name and on his
behalf necessary to give effect thereto.

 

	19.	RESTRICTIONS AFTER TERMINATION

 

	19.1.	Definitions

 

Since the Executive is likely to obtain
Confidential Information in the course of the Employment and personal knowledge of and influence over suppliers, customers, clients and
employees of the Company and Group Companies, the Executive hereby agrees with the Company that in addition to the other terms of this
Agreement and without prejudice to the other restrictions imposed upon him by law, he will be bound by the covenants and undertakings
contained in Clauses 19.2 to 19.7. In this Clause 19, unless the context otherwise requires:

 

    20

     

    

 

	“Customer”	means any person to which the Company distributed, sold or supplied Restricted Products or Restricted Services during the Relevant Period and with which, during that period either the Executive, or any employee under the direct or indirect supervision of the Executive, had material dealings in the course of the Employment, or about which the Executive had Confidential Information, but always excluding therefrom, any division, branch or office of such person with which the Executive and/or any such employee had no dealings during that period and about which the Executive had no Confidential Information;
	“Prospective Customer”	means any person with which the Company had discussions during the Relevant Period regarding the possible distribution, sale or supply of Restricted Products or Restricted Services and with which during such period the Executive, or any employee who was under the direct or indirect supervision of the Executive, had material dealings in the course of the Employment, or about which the Executive had Confidential Information, but always excluding therefrom any division, branch or office of that person with which the Executive and/or any such employee had no dealings during that period and about which the Executive had no Confidential Information;
	“Relevant Period”	means: (i) where the Employment is continuing, the period of the Employment; and (ii) where the Employment has terminated, the period of twelve months immediately preceding the Termination Date;
	“Restricted Area”	means:
	 	
    (a)           England,
Scotland and Wales;

     

    (b)           the United States of America;

     

    (c)           Austria;

     

    (d)           Japan;
and

     

    (e)         any
other country in the world where, on the Termination Date, the Company dealt in Restricted Products or Restricted Services;

     

	“Restricted Employee” 	means any person who was a director, employee or consultant of the Company at any time within the Relevant Period who by reason of that position and in particular his seniority and expertise or knowledge of Confidential Information or knowledge of or influence over the clients, customers or contacts of the Company is likely to cause damage to the Company if he were to leave the employment of the Company and become employed by a competitor of the Company;

 

    21

     

    

 

 

	 	“Restricted Period”	means the period commencing on the Termination Date and, subject to the terms of Clause 19.4, continuing for 12 months;
	 	“Restricted Products”	means any products, equipment or machinery researched into, developed, manufactured, supplied, marketed, distributed or sold by the Company (on its own or in collaboration or partnership with others) and with which the duties of the Executive were materially concerned or for which he was responsible during the Relevant Period or about which he had Confidential Information, or any products, equipment or machinery of the same type or materially similar to those products, equipment or machinery;
	 	“Restricted Services”	means any services (including but not limited to technical and product support, technical advice and customer services) researched into, developed or supplied by the Company (on its own or in collaboration or partnership with others) and with which the duties of the Executive were materially concerned or for which he was responsible during the Relevant Period or about which he had Confidential Information, or any services of the same type or materially similar to those services;
	 	“Supplier”	means any supplier, agent, distributor or other person who, during the Relevant Period was in the habit of dealing with the Company and with which, during that period, the Executive, or any employee under the direct or indirect supervision of the Executive, had material dealings in the course of the Employment, or about which the Executive had Confidential Information.

 

		19.2.	Restrictive covenants

 

Both during the Employment and during
the Restricted Period, the Executive will not, without the prior written consent of the Board, whether by himself, through his employees
or agents and whether on his own behalf or on behalf of any person, directly or indirectly:

 

		(a)	so as to compete with the Company, solicit business from or canvas or approach any Customer or Prospective
Customer in respect of Restricted Products or Restricted Services;

 

		(b)	so as to compete with the Company, accept orders from, act for or have any business dealings with, any
Customer or Prospective Customer in respect of Restricted Products or Restricted Services;

 

		(c)	within the Restricted Area, be employed, engaged or interested in or provide Confidential Information
to that part of a business or person which is involved in Restricted Products or Restricted Services, if the business or person is or
seeks to be in competition with the Company. For the purposes of this sub-clause, acts done by the Executive outside the Restricted Area
shall nonetheless be deemed to be done within the Restricted Area where their primary purpose is to distribute, sell, supply or otherwise
deal with Restricted Products or Restricted Services in the Restricted Area;

 

    22 

     

    

 

		(d)	solicit or induce or endeavour to solicit or induce any person who was a Restricted Employee (and with
whom the Executive had dealings during the Relevant Period) to cease working for or providing services to the Company, whether or not
any such person would thereby commit a breach of contract;

 

		(e)	employ or otherwise engage any Restricted Employee in the business of Restricted Products or Restricted
Services if that business is, or seeks to be, in competition with the Company;

 

		(f)	solicit or induce or endeavour to solicit or induce or approach any Supplier to cease to deal with the
Company and shall not interfere in any way with any relationship between a Supplier and the Company; or

 

		(g)	so as to compete with the Company or reduce the Company’s business, solicit, deal with, or attempt
to solicit or deal with any entity with whom it has entered into a collaboration agreement (or with whom it is in discussions to enter
into a collaboration agreement), and with which entity the Executive has had business dealings during the Relevant Period or about which
the Executive has Confidential Information.

 

		19.3.	Application of restrictive covenants to other Group Companies

 

Clause 19.2 shall also apply as though
references to the “Company” in Clauses 19.1 and 19.2 include references to each Group Company in relation to which the Executive
has in the course of the Employment or by reason of rendering services to or holding office in such Group Company:

 

		(a)	acquired knowledge of its products, services, trade secrets or Confidential Information; or

 

		(b)	had personal dealings with, or Confidential Information about, its Customers or Prospective Customers;
or

 

		(c)	supervised directly or indirectly employees having personal dealings with its Customers or Prospective
Customers;

 

but so that references to the “Company”
shall for this purpose be deemed to be references to the relevant Group Company. The obligations undertaken by the Executive pursuant
to this Clause 19.3 shall, with respect to each Group Company, constitute a separate and distinct covenant in favour of and for the benefit
of each Group Company and which shall be enforceable either by the particular Group Company or by the Company on behalf of the Group Company
and the invalidity or unenforceability of any such covenant shall not affect the validity or enforceability of the covenants in favour
of any other Group Company.

 

		19.4.	Effect of suspension on Restricted Period

 

If the Company exercises its right to
suspend the Executive’s duties and powers under Clause 5.2 after notice of termination of the Employment has been given, the aggregate
of the period of the suspension and the Restricted Period shall not exceed 12 months and if the aggregate of the two periods would exceed
12 months, the Restricted Period shall be reduced accordingly.

 

    23 

     

    

 

Further undertakings

 

The Executive hereby undertakes
to the Company that he will not at any time:

 

		(a)	during the Employment or after the Termination Date engage in any trade or business outside the Group
or be associated with any person engaged in any trade or business using any trading names used by the Company or any Group Company including
any of the names or incorporating any of the words “Exscientia” or “Kinetic Discovery”;

 

		(b)	after the Termination Date make any public statement in relation to the Company or any Group Company or
any of their directors, officers or employees or any product or service being sold or developed by the Company or any Group Company; or

 

		(c)	after the Termination Date represent or otherwise indicate any ongoing association or connection with
the Company or any Group Company (except as a shareholder, if that is the case).

 

		19.5.	Protection of Company reputation

 

The Executive undertakes that, he will
not at any time during the Employment and at any time (without limit) after the Termination Date make or publish or cause to be made or
published to anyone in any circumstances any disparaging remarks concerning the Company or any Group Company or any of its or their respective
shareholders, directors, officers, employees, consultants or agents or any product or service being sold or developed by the Company or
any Group Company. However, this shall not apply to any protected disclosure by the Executive within the meaning of section 43A of the
Employment Rights Act 1996.

 

		19.6.	Employment Offer

 

In the event that the Executive receives
a written offer of employment or request to provide services either during the Employment or during the terms of the Restricted Period,
the Executive shall:

 

		(a)	provide immediately to such person, company or other entity making such an offer or request a full and
accurate copy of the Restrictive Covenants set out at Clause 19 of this Agreement; and

 

		(b)	notify the Company within 5 working days of receipt of the offer and the identity of the person, company
or other entity making the offer.

 

		19.7.	Severance

 

The restrictions in this Clause 19 (on
which the Executive has had the opportunity to take independent advice, as the Executive hereby acknowledges) are separate and severable
restrictions and are considered by the parties to be reasonable in all the circumstances. It is agreed that if any such restrictions,
by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the
legitimate interests of the Company or a Group Company but would be adjudged reasonable if some part of it were deleted, the relevant
restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and enforceable.

 

    24 

     

    

 

		20.	RECONSTRUCTION AND AMALGAMATIONS

 

If the Company undergoes any process
of reconstruction or amalgamation (whether or not involving the liquidation of the Company) and the Executive is offered employment by
the successor or proposed successor to the Company or any Group Companies on terms not materially less favourable overall to those under
this Agreement whether as to duties, responsibilities, remuneration or otherwise and the Executive does not accept the offer within one
month of it being made, then the Executive shall have no claim in respect of termination of this Agreement and the Employment.

 

		21.	DISCIPLINARY AND GRIEVANCE PROCEDURE 

 

		21.1.	Disciplinary procedures

 

Any disciplinary action taken in connection
with the Employment will usually be taken in accordance with the Company’s normal disciplinary procedures (which are workplace rules
and not contractually binding) a copy of which is available from the Company’s Human Resources department.

 

		21.2.	Grievance procedure

 

If the Executive wishes to obtain redress
of any grievance relating to the Employment or is dissatisfied with any reprimand, suspension or other disciplinary step taken by the
Company, he shall apply in writing to the chairman of the Board, setting out the nature and details of any such grievance or dissatisfaction.

 

		22.	GENERAL

 

		22.1.	Provisions which survive termination 

 

Any provision of this Agreement which
is expressed or intended to have effect on, or to continue in force after, the termination of this Agreement shall have such effect, or,
as the case may be, continue in force, after such termination.

 

		22.2.	No collective agreements

 

There are no collective agreements
that directly affect the terms and conditions of the Employment.

 

		22.3.	Compliance 

 

The Executive shall comply with the
relevant obligations under prevailing law and regulation, including the Companies Act 2006, the requirements of the Nasdaq Stock Market
and the U.S. Securities and Exchange Commission requirements (in each case to the extent applicable) or other laws applicable to the Parent
and the Company from time to time as may be notified to the Executive.

 

		23.	DATA PROTECTION AND PRIVACY

 

		23.1.	Data Protection

 

The Company will hold, collect and otherwise
process certain personal data as set out in the Company’s privacy notice, which is in the Company’s Staff Handbook. All personal
data will be treated in accordance with applicable data protection laws and regulations.

 

    25 

     

    

 

		24.	AMENDMENTS, WAIVERS AND REMEDIES

 

		24.1.	Amendments

 

No amendment or variation of this Agreement
or any of the documents referred to in it shall be effective unless it is in writing and (other than an alteration in the Basic Salary)
signed by or on behalf of each of the parties.

 

		24.2.	Waivers and remedies cumulative

 

		(a)	The rights of each party under this Agreement:

 

		(i)	may be exercised as often as necessary;

 

		(ii)	are cumulative and not exclusive of its rights under the general law; and

 

		(iii)	may be waived only in writing and specifically.

 

		(b)	Delay in exercising or non-exercise of any right is not a waiver of that right.

 

		(c)	Any right of rescission conferred upon the Company by this Agreement shall be in addition to and without
prejudice to all other rights and remedies available to it.

 

		25.	ENTIRE AGREEMENT

 

		(a)	This Agreement and the documents referred to in it constitute the entire agreement and understanding of
the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings
between the parties, whether written or oral, relating to the subject matter of this Agreement.

 

		(b)	Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies
in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this
Agreement.

 

		(c)	Each party agrees that it shall have no claim for innocent or negligent misrepresentation or negligent
misstatement based on any statement in this Agreement.

 

		(d)	Nothing in this Clause shall limit or exclude any liability for fraud.

 

		26.	NO OUTSTANDING CLAIMS

 

The Executive hereby acknowledges that
as at the Effective Date he has no outstanding claims of any kind against the Company or any Group Company (other than in respect of remuneration
and expenses due to the date of this Agreement but not yet paid).

 

		27.	SEVERANCE

 

If any provision of this Agreement is
or becomes illegal, invalid or unenforceable in any jurisdiction, that shall not affect:

 

		(a)	the legality, validity or enforceability in that jurisdiction of any other provisions of this Agreement;
or

 

		(b)	the legality, validity or enforceability in any other jurisdiction of that or any other provision of this
Agreement.

 

    26 

     

    

 

		28.	NOTICE

 

		28.1.	Notices and deemed receipt

 

Any notice hereunder shall be given
by either party to the other either personally to the Executive or (where notice is to be given to the Company) the Chairman or the Head
of Human Resources or sent in the case of the Company, to its registered office for the time being and, in the case of the Executive,
to his address last known to the Company or sent by email to, in the case of the Company, the Company email address of the Chairman and
the Head of Human Resources and, in the case of the Executive, his Company email address. Any such notice shall be in writing and shall
be given by letter delivered by hand or sent by first class prepaid recorded delivery or registered post or by email transmission. Any
such notice shall be deemed to have been received:

 

		(a)	if delivered personally, at the time of delivery;

 

		(b)	in the case of pre-paid recorded delivery or registered post, 48 hours from the date of posting;

 

		(c)	in the case of registered airmail, five days from the date of posting; and

 

		(d)	in the case of email, at the time of transmission;

 

provided that if deemed receipt occurs
before 9am on a business day the notice shall be deemed to have been received at 9am on that day and if deemed receipt occurs after 5pm
on a business day, or on a day which is not a business day, the notice shall be deemed to have been received at 9am on the next business
day. For the purpose of this Clause, “business day” means any day which is not a Saturday, a Sunday or a public holiday in
the place at or to which the notice is left or sent. This clause does not apply to the service of any proceedings or other documents in
any legal action or, where applicable, any arbitration or other method of dispute resolution.

 

		28.2.	Electronic service

 

For the avoidance of doubt,
notice given under this Agreement shall be validly served if sent by email.

 

		29.	GOVERNING LAW AND JURISDICTION

 

		29.1.	Governing law

 

This Agreement is governed
by and to be construed in accordance with English law.

 

		29.2.	Jurisdiction

 

Each party hereby submits to the non-exclusive
jurisdiction of the English courts as regards any claim, dispute or matter arising out of or in connection with this Agreement and its
implementation and effect.

 

    27 

     

    

 

IN WITNESS of which
this Agreement has been executed and delivered as a deed on the first date written above.

 

	EXECUTED as a Deed by EXSCIENTIA AI 

LIMITED acting by ANDREW HOPKINS	
    /s/ Andrew Hopkins

	 	Director
	 	 
	Witness’s	 
	 	 
	Signature:	
/s/ Dan Ireland
	 	 
	Full Name:	
Dan Ireland
	 	 
	Address:	
The Schrodinger Building
	 	
Oxford Science Park
	 	 
	 	 

 

	EXECUTED as a Deed by 

BEN TAYLOR in the presence of:	
    /s/ Ben Taylor

	 	 
	 	 
	Witness’s	 
	 	 
	Signature:	
/s/ Dan Ireland
	 	 
	Full Name:	
Dan Ireland
	 	 
	Address:	
The Schrodinger Building
	 	
Oxford Science Park
	 	
OX4 4GEExhibit 10.10

 

SUBSCRIPTION AGREEMENT

 

THIS SUBSCRIPTION
AGREEMENT (this “Agreement”) is made and entered into as of September 24, 2021 (the “Effective
Date”), by and between:

 

		(1)	EXSCIENTIA PLC (registered number 13483814), a public limited company incorporated in England and
Wales whose registered office is The Schrodinger Building, Oxford Science Park, Oxford, OX4 4GE, Oxfordshire, United Kingdom (the “Company”);
and

 

		(2)	SVF II EXCEL (DE) LLC, a Delaware company, having its principal place of business at 251 Little
Falls Drive, Wilmington, DE 19808, USA (the “Subscriber”).

 

BACKGROUND:

 

		(A)	WHEREAS, the Subscriber is the holder of 44,318 Series D1 preference shares of £0.16 each
in the capital of the Company.

 

		(B)	WHEREAS, the Company and the Subscriber desire to enter into this Agreement pursuant to which the
Subscriber agrees to subscribe for US$125,000,000 of the Company’s American Depositary Shares (“ADSs”), each
ADS representing one of the ordinary shares of £0.0005 each in the capital of the Company (the “Ordinary Shares”)
in a private placement that will close concurrently with the Company’s initial public offering (“IPO”) of ADSs
as described herein.

 

NOW, THEREFORE, in consideration
of the foregoing recitals and the mutual promises, warranties, and covenants hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

		1.	SUBSCRIPTION

 

Subject to the terms
and conditions hereof, in the event that the Company consummates an IPO pursuant to an effective registration statement (the “Registration
Statement”) under the U.S. Securities Act of 1933, as amended (the “Securities Act”), the Subscriber shall,
in a concurrent private placement exempt from the registration requirements of the Securities Act, subscribe for that number of ADSs,
rounded down to avoid fractional ADSs (the “Securities”), determined by dividing US$125,000,000 (one hundred and twenty
five million U.S. dollars) (the “Subscription Amount”) by the price per ADS at which the ADSs are offered for subscription
to the public in the IPO, as set forth on the cover page of the final prospectus for the IPO (the “IPO Price”) and
such purchase will occur concurrently with, and be conditioned upon, the closing of the IPO.

 

		2.	AGREEMENT TO SUBSCRIBE

 

		2.1.	Subscription for the Securities

 

Subject to the terms
and conditions hereof, the Subscriber hereby applies for and agrees to subscribe for, and the Company accepts such application and will
allot and issue to the Subscriber, in a concurrent private placement exempt from the registration requirements of the Securities Act,
the Securities at a subscription price per ADS equal to the IPO Price.

 

    1

    

    

 

		2.2.	Closing Date

 

The subscription for
the Securities (the “Closing”) shall take place, subject to the satisfaction or waiver of the Conditions (other than
those Conditions that are to be satisfied on the Closing) simultaneously with the closing of the IPO at such place as may be mutually
agreed between the Company and the Subscriber (the date of such Closing is hereinafter referred to as the “Closing Date”).

 

		2.3.	Actions by the Subscriber and the Company at Closing

 

At the Closing, the
Subscriber shall pay the Subscription Amount by wire transfer of immediately available funds to an account specified in writing by the
Company and provided to the Subscriber no later than two business days prior to the Closing Date and, subject to receipt thereof, the
Company will issue the Securities by (a) causing the CREST account of the nominee of Citibank, N.A., the Company’s depositary for
its ADS program (the “Depositary”), to be credited with the Securities issued and sold hereunder and (b) instructing
the Depositary to issue restricted, uncertificated ADSs evidencing the Securities in the name of the Subscriber, in an account of the
Company’s restricted ADS facility and provide evidence of the same to the Subscriber no later than five business days after the
Closing Date.

 

		3.	WARRANTIES OF THE COMPANY

 

Except as may be disclosed
in the Registration Statement or separately provided by the Company to the Subscriber prior to the date hereof, the Company hereby warrants
to the Subscriber as follows as of the date hereof and as of the Closing Date (except for the warranties that speak as of a specific date,
which shall be made as of such date):

 

		3.1.	Organisation; Qualification

 

The Company is a company
duly incorporated, validly existing and in good standing under the laws of England and Wales and has all requisite corporate power and
authority to carry on its business as now conducted. The Company has at all times complied with all provisions of its articles of association
(the “Articles”) and is not in default under, or in violation of, any such provision of the Articles. The Company is
not, and has never been, a “shell company,” as described in paragraphs (i)(1)(i) and (ii) of Rule 144 promulgated under the
Securities Act.

 

		3.2.	Capitalisation

 

The issued share capital
of the Company and details of the securities convertible, exercisable or exchangeable therefor as of immediately prior to the Closing,
including the holders thereof, are disclosed in the Registration Statement.

 

		3.3.	Authorisation; Binding Obligations

 

The Company has
all requisite power and authority to execute and deliver this Agreement and any and all instruments necessary or appropriate in
order to effectuate fully the terms and conditions contained herein and all related transactions and to perform its obligations
hereunder. This Agreement and the allotment, issuance, and delivery of the Securities have been duly authorised by all necessary
action on the part of the Company, and the Agreement has been duly executed by the Company and constitutes the valid and legally
binding obligation of the Company enforceable in accordance with its terms and conditions. The authorisation, allotment, issuance,
and delivery of the Securities have been duly authorised by all requisite action of the Company’s board of directors (the
 “Board”) and shareholders.

 

    2

    

    

 

		3.4.	Valid Issuance of the Securities; Exemption from Registration

 

When issued in accordance
with this Agreement, the ADSs and underlying Ordinary Shares will be (i) duly and validly issued, fully paid, free of any liens, options,
encumbrances, proxies, adverse claims or restrictions imposed by the Company except as set forth in the Companies Act 2006 or the Articles
and (ii) assuming the accuracy of the Subscriber’s warranties in this Agreement at the time of such issuance, exempt from registration
and/or qualification under the Securities Act and all applicable U.S. state securities laws, and issued in compliance with all applicable
securities laws.

 

		3.5.	Non-Contravention

 

No consent, approval,
notice, order or authorisation of, or registration, qualification, designation, declaration or filing with, any U.S. or UK governmental
authority (other than filings required to be made in accordance with the Companies Act 2006) on the part of the Company or the Depositary
is required in connection with (i) the authorisation and execution of this Agreement or (ii) the authorisation, allotment and issuance
of the Securities pursuant to this Agreement. The Company is not in violation or default of any instrument, judgment, order, writ, decree
or contract to which the Company is a party or by which the Company is bound or of any provision of any statute, rule or regulation applicable
to the Company, which violation or default would materially and adversely affect the business of the Company.

 

		3.6.	Compliance with Securities Laws; No Integration

 

Assuming the accuracy
of the Subscriber’s warranties, (i) no registration of the Securities is required under the Securities Act or any applicable US
state securities laws in connection with the allotment and issue of the Securities to the Subscriber and (ii) the allotment and issuance
of the Securities to the Subscriber will not be in violation of the Articles, in each case when such Securities are allotted and issued
in accordance with this Agreement. Neither the Company nor its subsidiaries or any affiliates, nor any person acting on its or their behalf,
has, directly or indirectly, made any offers or sales of any ADSs or Ordinary Shares under circumstances that would adversely affect reliance
by the Company on Section 4(a)(2) and Regulation D of the Securities Act for the exemption from registration of Securities issued pursuant
to a private placement, as contemplated by this Agreement, or would otherwise require registration of the Securities under the Securities
Act as an integrated offering.

 

		3.7.	Investment Company

 

The Company is not
and, immediately after giving effect to the allotment and issue of the Securities, will not be required to register as an “investment
company” as defined in the Investment Company Act of 1940, as amended.

 

    3

    

    

 

		3.8.	No General Solicitation

 

Except with respect
to the ADSs sold in the IPO, neither the Company nor its subsidiaries or any affiliates, nor any person acting on its or their behalf,
has offered or sold any of the Securities by any form of general solicitation or general advertising.

 

		3.9.	IPO Registration Statement

 

The IPO Registration
Statement filed with the Securities and Exchange Commission (the “Commission”) conforms, and the final prospectus forming
a part of the Registration Statement (the “Prospectus”) and any further amendments or supplements to the Registration
Statement or the Prospectus, will conform, in all material respects, to the requirements of the Securities Act and the rules and regulations
of the Commission thereunder and do not and will not, as of the applicable effective date as to the Registration Statement and any amendment
thereto, and as of its date as to the Prospectus and any amendment or supplement thereto, contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

 

		3.10.	“Bad Actor” Status

 

Neither the Company nor any of its Rule
506(d) Related Parties (as defined below) is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities
Act. For purposes of this Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by the “Bad
Actor disqualification” provision of Rule 506(d) of the Securities Act.

 

		4.	WARRANTIES OF THE SUBSCRIBER

 

		4.1.	Investment Warranties

 

		(a)	The Subscriber warrants to the Company that: (i) it is an “accredited investor” as defined
in Rule 501(a) of Regulation D of the Securities Act; (ii) it has sufficient knowledge and experience in investing in companies similar
to the Company in terms of the Company’s stage of development, so as to be able to evaluate the risks and merits of its investment
in the Company and it is able financially to bear the risks thereof; (iii) it has had an opportunity to discuss the Company’s business,
management and financial affairs with the Company’s management; and (iv) its financial condition is such that it is able to bear
the risk of holding the Securities for an indefinite period of time and can bear the loss of the entire investment in such securities.

 

		(b)	This Agreement is made in reliance upon the Subscriber’s express representations that (i) the Securities
being subscribed for by the Subscriber are being acquired for the Subscriber’s own account (and not on behalf of any other person
or entity) and not with a view to, or for sale in connection with, the distribution thereof, nor with any present intention of distributing
or selling the Securities or any portion thereof, (ii) the Subscriber was not organised for the specific purpose of acquiring the Securities
and (iii) the Securities will not be sold by the Subscriber without registration under the Securities Act and applicable state securities
laws, or an exemption therefrom.

 

		(c)	Subject to Section 7.2, the Subscriber understands that until such time as the Securities shall have been
registered under the Securities Act and applicable state securities laws or shall have been transferred in accordance
with an opinion of counsel reasonably satisfactory to the Company and the Depositary that such registration is not required, stop transfer
instructions shall be issued to the Company’s Depositary, and any certificate or certificates representing such Securities shall
bear a restrictive legend stating that such Securities have not been registered under the Securities Act and applicable state securities
laws and referring to restrictions on the transferability and sale thereof. The Subscriber further understands that its warranties hereunder
will not preclude disposition of the Securities without registration thereof, in compliance with Rule 144 promulgated under the Securities
Act (“Rule 144”) or any other applicable exemption under the Securities Act.

 

    4

    

    

 

		4.2.	Receipt of Information

 

The Subscriber believes
it has received all the information the Subscriber considers necessary or appropriate for deciding whether to purchase the Securities.
The Subscriber has been afforded an opportunity to ask questions of and receive answers from representatives of the Company concerning
the terms and conditions of this Agreement, the subscription for the Securities, the Company’s business, operations, market potential,
capitalisation, financial condition and prospects, and all other matters deemed relevant by the Subscriber. The foregoing, however, does
not limit or modify the warranties of the Company in Section 3 of this Agreement.

 

		4.3.	Authorisation

 

The Subscriber has
all requisite power and authority to execute and deliver this Agreement. This Agreement constitutes the valid and legally binding obligation
of the Subscriber, enforceable against the Subscriber in accordance with its terms.

 

		4.4.	“Bad Actor” Status

 

The Subscriber hereby
warrants that neither it nor any of its Rule 506(d) Related Parties is a “bad actor” within the meaning of Rule 506(d) promulgated
under the Securities Act.

 

		4.5.	Legends

 

The Subscriber understands
and agrees that the certificates or confirmations evidencing or confirming the Securities, or any other securities issued in respect of
the Securities upon any share split, share consolidation, recapitalisation, or similar event, shall bear the restrictive legend in substantially
the following form, subject to Section 7.2.

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT RELATED THERETO AND COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, A VALID
EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS.”

 

    5

    

    

 

		4.6.	Restricted ADS Facility

 

The Subscriber agrees
that it shall not, prior to the day on which the Securities have become freely transferrable under the Securities Act and under any terms
of this Agreement including but not limited to Section 6.1 and Section 7, deposit the Securities into the unrestricted ADS facility of
the Company with the Depositary nor request the issuance of by such depositary of any unrestricted ADSs or American Depositary Receipts
in respect of the Securities.

 

		5.	CONDITIONS TO CLOSING (THE “CONDITIONS”)

 

		5.1.	Conditions to the Subscriber’s Obligations at the Closing 

 

The obligations of
the Subscriber under this Agreement are subject to the satisfaction (or, if permitted by law, waiver in writing by the Subscriber), at
or prior to the Closing Date, of the following conditions:

 

		(a)	No Injunction, etc. No preliminary or permanent injunction or other binding order, decree or ruling
issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions
contemplated by this Agreement. No action or claim shall be pending before any court or quasi-judicial or administrative agency of any
federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree, ruling
or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause
any of the transactions contemplated by this Agreement to be rescinded following consummation or (iii) have the effect of making illegal
the purchase of, or payment for, any of the Securities by the Subscriber.

 

		(b)	Warranties True. The warranties in Section 3 made by the Company shall be true and correct in all
material respects (except for such warranties that are qualified by materiality, which shall be true and correct in all respects) on and
as of the Closing Date with the same effect as though such warranties had been made on and as of such date, except to the extent expressly
made as of a specified date, which shall be true and correct as of such date.

 

		(c)	Performance. The Company shall have performed and complied with all covenants, agreements, obligations
and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing Date.

 

		(d)	Securities Law Compliance. The offer and sale of the Securities to the Subscriber pursuant to this
Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements
of all applicable state securities laws.

 

		(e)	Consents, Permits, and Waivers. All consents, permits and waivers, if any, of any governmental
authority or regulatory body that are required in connection with the transactions contemplated by this Agreement shall have been duly
obtained and shall be effective on and as of the Closing.

 

    6

    

    

 

		5.2.	Conditions to obligations of the Company

 

The obligations of
the Company under this Agreement are subject to the satisfaction (or, if permitted by law, waiver in writing by the Company), on or prior
to the Closing Date, of the following conditions:

 

		(a)	Warranties True. The warranties in Section 4 made by the Subscriber shall be true and correct in
all material respects (except for such warranties that are qualified by materiality which shall be true and correct in all respects) on
and as of the Closing with the same effect as though such warranties had been made on and as of the Closing.

 

		(b)	Performance. The Subscriber shall have performed and complied with all covenants, agreements, obligations
and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing Date.

 

		(c)	Securities Law Compliance. The offer and sale of the Securities to the Subscriber pursuant to this
Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements
of all applicable state securities laws.

 

		(d)	Consents, Permits, and Waivers. All consents, permits and waivers, if any, of any governmental
authority or regulatory body that are required in connection with the transactions contemplated by this Agreement shall have been duly
obtained and shall be effective on and as of the Closing.

 

		(e)	Lock-Up Agreement. The Subscriber shall have executed and delivered a lock-up agreement to the
underwriters for the IPO, and such agreement shall be in full force and effect as of the Closing and the Securities shall be subject to
the restrictions in such lock-up agreement.

 

		6.	COVENANTS AND AGREEMENTS

 

		6.1.	Standstill Provision

 

Subject to Section
6.2 of this Agreement, during the six month period commencing on the effective date of the IPO Registration Statement (the “Standstill
Period”), without the prior written approval of the Board, neither the Subscriber, any of the Subscriber’s controlled
Affiliates nor any of the Subscriber’s representatives acting on behalf of or in concert with the Subscriber will, in any manner,
directly or indirectly:

 

		(a)	make, effect, initiate or participate in (i) any acquisition of beneficial ownership of any voting securities
of the Company (“Voting Securities”) (including derivatives thereof) or debt securities, except as a result of a share
sub-division, share dividend or other pro rata distribution made by the Company to its shareholders and in which the Subscriber participates
solely in its capacity as a shareholder of the Company or (ii) any acquisition of all or a material portion of the assets of the Company
and its subsidiaries on a consolidated basis (iii) any tender offer, takeover offer, exchange offer, merger, business combination, scheme
of arrangement, recapitalisation, restructuring, liquidation, dissolution or extraordinary transaction involving the Company or any subsidiary
of the Company or involving any securities or assets of the Company or any securities or assets of
any subsidiary of the Company (provided that the Subscriber may tender its securities in any tender or exchange offer made by any third
party provided that the Subscriber is not in breach of Section 6.1 of this Agreement), or (iv) any “solicitation” of “proxies”
(as those terms are used in the proxy rules of the Commission) or consents with respect to the Voting Securities;

 

    7

    

    

 

		(b)	form, join or participate in a “group” (as defined in the Exchange Act and the rules promulgated
thereunder) with respect to the beneficial ownership of any Voting Securities or debt securities of the Company or any subsidiary or division
of the Company;

 

		(c)	act, alone or in concert with others, to seek to control or influence the management, the Board or policies
of the Company in contravention of the other subsections of this Section 6.1;

 

		(d)	take any action that would reasonably be expected to cause the Company, the Subscriber or any other person
to be required under applicable securities laws to make a public announcement regarding any of the types of matters set forth in Subsection
6.1(a);

 

		(e)	agree or offer to take, or knowingly encourage or propose (publicly or otherwise) the taking of, any action
referred to in Subsections 6.1(a), 6.1(b), 6.1(c), or 6.1(d);

 

		(f)	assist, induce or encourage any other Person to take any action of the type referred to in Subsections
6.1(a), 6.1(b), 6.1(c), 6.1(d) or 6.1(e) (provided that the Subscriber shall not be deemed to be in violation of this clause (f) unless
the person providing such assistance, inducement or encouragement knew or reasonably should have known at the time he or she did so that
doing so violated this Section 6.1, or knew or reasonably should have known after such time and did not attempt to halt such actions);

 

		(g)	enter into any discussions, negotiations, arrangement or agreement with any other Person with the intent
to effect any of the foregoing (provided that the Subscriber shall not be deemed to be in violation of this clause 6.1(g) with respect
to discussions or negotiations unless the person entering into such discussions or negotiations knew or reasonably should have known at
the time he or she did so that doing so violated this Section 6.1 or knew or reasonably should have known after such time and did not
attempt to halt such actions); or

 

		(h)	request or propose (either directly or indirectly) that the Company or any of the Company’s representatives
amend, waive or consider the amendment or waiver of any provision set forth in this Section 6 (including this sub-paragraph).

 

    8

    

    

 

Notwithstanding any
other provision of this Agreement to the contrary, (i) nothing in this Section 6.1 will be deemed to prohibit the Subscriber from confidentially
communicating to the Board or the Company’s senior management or external financial advisors any non-public proposals regarding
a possible transaction of any kind in such a manner as would not reasonably be expected to (x) require public disclosure thereof under
applicable law or listing standards of any securities exchange or (y) require either the Company or the Subscriber to take any public
action under applicable law or listing standards of any securities exchange and (ii) this Section 6.1 shall terminate upon a Fundamental
Change Event. “Fundamental Change Event” means:

 

		(a)	the Company enters into, or publicly announces the intention to enter into, a definitive written agreement
with any Person other than the Subscriber (or any of its Affiliates) to consummate a merger, consolidation or similar transaction pursuant
to which (1) any Person other than the Subscriber (or any of its Affiliates) will acquire 50% or more of the issued voting share capital
of the Company or (2) the Company and its subsidiaries will sell to any Person other than the Subscriber (or any of its Affiliates) all
or substantially all of the consolidated assets of the Company and its consolidated subsidiaries;

 

		(b)	the Board of Directors of the Company recommends to the shareholders of the Company any acquisition by
any Person of all or more than 50% of the issued voting share capital of the Company or all or substantially all of the consolidated assets
of the Company and its consolidated subsidiaries;

 

		(c)	any Person or “group” (as defined in the Exchange Act and the rules promulgated thereunder)
that is or includes a company (other than the Subscriber, any of the Subscriber’s controlled Affiliates) that is in the business
of developing, marketing, selling or manufacturing human therapeutics (such company, a “Pharmaceutical Company”) acquires,
or publicly announces a proposal or intention to acquire, Voting Securities representing 25% or more of the then outstanding Voting Securities;
or

 

		(d)	any Person or “group” that is or includes a Pharmaceutical Company commences a tender or exchange
offer to acquire 50% or more of the issued voting share capital of the Company.

 

Notwithstanding the
foregoing, a Fundamental Change Event shall not include any internal reorganisation transactions involving only the Company, one or more
of its subsidiaries and/or any holding company formed for the purpose of such transactions. In addition, nothing contained herein shall
limit the ability of the Company to make any disclosures required by applicable law. The expiration of the Standstill Period will not
terminate or otherwise affect any other of the provisions of this Agreement. For purposes of Section 6, (y) “Affiliate”
has the meaning set forth in Rule 12b-2 of the regulations promulgated under the Exchange Act and includes, with respect to the Subscriber,
an affiliated fund under common management or control with the Subscriber or a fund or an account which investments are managed by the
investment manager of the Subscriber or an investment manager under common management or control with the Subscriber’s investment
manager and (z) “Voting Securities” shall mean at any time securities of any class of the share capital of the Company
which are entitled to vote generally in the election of directors including but not limited to ADSs and Ordinary Shares.

 

		6.2.	Restrictions on Transfer

 

		(a)	Until the expiration or earlier termination of the Standstill Period, the Subscriber will not Transfer
any Securities; provided, however, that the Subscriber shall be permitted to Transfer any portion or all of its Securities, at any time
under the following circumstances:

 

		(i)	Transfers to any of its Affiliates, but only upon notice in writing to the Company and provided the
                                                             transferee agrees in writing for the benefit of the Company (in form and substance reasonably satisfactory to the Company) to be
                                                             bound by the terms and conditions of this
Agreement and if the transferee and the transferor agree for the express benefit of the Company that the transferee shall Transfer Securities
so Transferred back to the transferor at or before such time the transferee ceases to be an Affiliate of the transferor.

 

    9

    

    

 

		(ii)	Transfers that have been approved in writing by the Board.

 

		(iii)	Transfers in connection with the creation of any charge, lien, mortgage, pledge or other security interest
or posting as collateral any of the Transfer Securities in connection with a bona fide loan transaction with a nationally or internationally
recognized financial institution acting as lender; provided that such a loan is not contractually set to mature during the Standstill
Period and the Securities and any derivative instruments transferred in connection with such a loan remain subject to the terms of this
Agreement and any lender transferee agrees in writing to be bound by the restrictions set forth herein.

 

		(b)	In the event of any Transfer by the Subscriber of its Securities, the Subscriber shall notify the Company
in writing of such Transfer. Additionally, in the event of any Transfer by the Subscriber to an Affiliate of the Subscriber, the pledgee,
transferee or donee shall furnish the Company with a written agreement to be bound by the provisions of this Agreement, including but
not limited to the provisions applicable to the Subscriber pursuant to this Section 6 (the “Transferee Agreement”).
In addition to any other conditions set forth in this Agreement or as otherwise required by the Company, such Transfer to an Affiliate
of the Subscriber shall not be valid unless and until the Company receives the Transferee Agreement. After the effectiveness of the Transfer,
such pledgee, transferee or donee shall be treated as the “Subscriber” for purposes of this Agreement.

 

		(c)	For purposes of this Section 6.2, “Transfer” by any Person means directly or indirectly,
to sell, transfer, assign, pledge, encumber, hypothecate or similarly dispose of, either voluntarily or involuntarily, or to enter into
any contract, option or other arrangement or understanding with respect to the sale, transfer, assignment, pledge, encumbrance, hypothecation
or similar disposition of, any securities beneficially owned by such Person or of any interest (including any voting interest) in any
securities beneficially owned by such Person. For the avoidance of doubt, a transfer of control of the direct or indirect beneficial ownership
of securities is a Transfer of such securities for purposes of this Agreement.

 

		7.	RULE 144

 

		7.1.	Rule 144 Reporting

 

With a view to making
available to the Subscriber the benefits of certain rules and regulations of the Commission which may permit the sale of the Securities
to the public without registration, the Company agrees to use commercially reasonable efforts to:

 

		(a)	make and keep public information available, as those terms are understood and defined in Rule 144(c);

 

    10

    

    

 

 

		(b)	file or furnish with the Commission in a timely manner all reports and other documents required of the
Company under the Exchange Act; and

 

		(c)	furnish the Subscriber forthwith upon request (i) a written statement by the Company as to its compliance
with the current public information requirement of Rule 144(c), (ii) an electronic copy of the most recent periodic report of the Company,
and (iii) such other reports and documents as may be reasonably requested in availing the Subscriber of any rule or regulation of the
Commission permitting the sale of any such securities without registration.

 

		7.2.	Removal of Restrictive Legend

 

Any ADSs representing
the Securities, when issued, shall not bear the restrictive legend set forth in Section 4.5: (i) following a sale of such Securities pursuant
to a registration statement covering the resale of such Securities, while such registration statement is effective under the Securities
Act, (ii) following any sale of such Securities pursuant to Rule 144, (iii) if such Securities are eligible for sale under Rule 144, without
the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Securities
and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities
Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company agrees that at such time
as the restrictive legend set forth in Section 4.5 is no longer required under this section, then no later than five (5) business days
following the later of (i) delivery by the Subscriber to the Company of customary representations regarding the facts to support the removal
of the restrictive legends; and (ii) delivery to the Depositary, as the case may be, the information reasonably required by the Depositary
in connection with such request, the Company shall (x) in the event that such Securities are certificated, deliver or cause to be delivered
to the Subscriber a certificate representing such Securities that is free from such restrictive legend, or (y) cause its Depositary, as
the case may be, to remove any such restrictive legend in the Company’s records of its share capital.

 

		7.3.	American Depositary Shares

 

For purposes of Section
6 and this Section 7, the term “Voting Securities” shall, as the context requires, be deemed to refer to any ADSs or Ordinary
Shares.

 

		8.	MISCELLANEOUS

 

		8.1.	Costs and Expenses

 

Each Party shall bear
its own costs and expenses in connection with negotiation of this Agreement. For the avoidance of doubt, the Subscriber will be responsible
for any fees of the depositary that arise regarding its Securities.

 

		8.2.	Governing Law

 

This Agreement and
any dispute or claim relating to it or its subject matter (including non- contractual claims) is governed by and is to be construed in
accordance with English law.

 

    11

     

    

 

		8.3.	Jurisdiction

 

The parties irrevocably
agree that the courts of England and Wales shall have exclusive jurisdiction to settle any claim, dispute or issue (including non-contractual
claims) which may arise out of or in connection with this Agreement or its enforceability.

 

		8.4.	Survival

 

The warranties of
the Company and the Subscriber contained in or made pursuant to this Agreement shall survive, any investigation made by the Subscriber,
the execution and delivery of this Agreement and the Closing.

 

		8.5.	Successors and Assigns

 

The terms and conditions
of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns
any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
Neither the Company nor the Subscriber shall have the right to assign this Agreement without the prior written consent of the other party.

 

		8.6.	Entire Agreement

 

This Agreement including
the exhibits and schedules attached hereto, constitutes the full and entire understanding and agreement between the parties with regard
to the subjects hereof and thereof and no party shall be liable for or bound to any other in any manner by any oral or written representations,
warranties, covenants and agreements except as specifically set forth herein and therein.

 

		8.7.	Severability

 

In the event one or
more of the provisions of this Agreement should, for any reason, be held by a court of competent jurisdiction to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement,
and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. Upon such
determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

 

		8.8.	Amendment and Waiver

 

This Agreement may
be amended or modified, and the rights and the obligations of the Company and the rights and obligations of the Subscriber may be waived,
only upon the written consent of the Company and the Subscriber.

 

		8.9.	Notices

 

All notices and other communications which are required or permitted
hereunder will be in writing and sufficient if delivered personally, sent by electronic mail or facsimile (and promptly confirmed by personal
delivery, registered or certified mail or overnight courier), sent by nationally-recognised overnight courier or sent by registered or
certified mail, postage prepaid, return receipt requested, addressed as follows:

 

    12

     

    

 

To the Company:                              Exscientia plc

The Schrodinger Building, Oxford Science Park, Oxford OX4
4GE, United Kingdom

Attention: Ben Taylor, CFO and Dan Ireland, VP, Legal

Email: brt@exscientia.ai and  legal@exscientia.co.uk

 

With a copy, which shall not constitute
notice, to:

 

Cooley (UK) LLP

22 Bishopsgate, London EC2N 4BQ

Attention: David Boles

Email: dboles@cooley.com

 

To Subscriber:                                  SVF II Excel (DE) LLC

69 Grosvenor Street, London W1K 3JP

Attention: Legal

Email: legal@softbank.com

 

or to such other address
as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such notice will
be deemed to have been given: (a) when delivered if personally delivered on a business day (or if delivered or sent on a non-business
day, then on the next business day); (b) on the business day of receipt if sent by overnight courier or electronic mail; or (c) on the
business day of receipt if sent by mail.

 

		8.10.	Titles and Subtitles

 

The titles of the
sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.

 

		8.11.	Counterparts

 

This Agreement may
be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.
Any or all parties may execute this Agreement by facsimile signature or scanned signature in PDF format and any such facsimile signature
or scanned signature, if identified, legible and complete, shall be deemed an original signature and each of the parties is hereby authorised
to rely thereon.

 

		8.12.	Broker’s Fees

 

Each party hereto
warrants that no agent, broker, investment banker, person or firm acting on behalf of or under the authority of such party hereto is or
will be entitled to any broker’s or finder’s fee or any other commission directly or indirectly in connection with this Agreement
or the transactions contemplated herein. Each party hereto further agrees to indemnify each other party for any claims, losses or expenses
incurred by such other party as a result of the warranties in this Section 8.13 being untrue.

 

    13

     

    

 

		8.13.	Termination

 

The parties hereto
may terminate this Agreement by mutual written agreement. This Agreement may be terminated by either the Subscriber or the Company on
written notice to the other party if Closing has not occurred before 31 December 2021.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK]

 

    14

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first set forth above.

 

	EXECUTED by EXSCIENTIA
PLC	)	
	 	 	 
	acting by a director	)	 
	 	 	 /s/ Andrew Hopkins
	 	)	 

 

	EXECUTED by SVF
II EXCEL (DE) LLC	)	
	 	 	 
	acting by an authorised signatory	)	 
	 	 	 /s/ Ian McLean
	 	)	 

 

    15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]